---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-118749"
form_type: "8-K"
ticker: "ACXP"
cik: "0001736243"
company_name: "Acurx Pharmaceuticals, Inc."
filed_at: "2023-11-15T23:59:59+00:00"
generated_at: "2026-06-08T02:37:30.248022+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Acurx Pharmaceuticals enters $17M ATM equity offering with A.G.P.

## Summary
- Up to $17M of common stock may be sold from time to time in at-the-market offerings.
- A.G.P./Alliance Global Partners acts as sales agent, receiving 3% of gross proceeds.
- Sales may be made on Nasdaq Capital Market, OTC, or in negotiated transactions.
- Company is not obligated to sell any shares under the agreement.
- Offering made under existing Form S-3 shelf registration statement declared effective July 2022.

## SEC filing metadata
- accession: 0001104659-23-118749
- form_type: 8-K
- ticker: ACXP
- cik: 0001736243
- company_name: Acurx Pharmaceuticals, Inc.
- filed_at: 2023-11-15T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1736243/000110465923118749/0001104659-23-118749-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1736243/000110465923118749/tm2330856d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-118749
- JSON: https://secwatch.observer/filing/0001104659-23-118749.json
- Plain text: https://secwatch.observer/filing/0001104659-23-118749.txt

## Key facts
- Material Agreements
  Acurx Pharmaceuticals, Inc. entered into Sales Agreement with A.G.P./Alliance Global Partners valued at up to $17.0 million (effective 2023-11-15).
  - Action: entry
  - Agreement: atm program
  - Counterparty: A.G.P./Alliance Global Partners
  - Value: up to $17.0 million
  - Effective: 2023-11-15
  source text: On November 15, 2023, Acurx Pharmaceuticals, Inc. (the “Company”) entered into a sales agreement (the “Sales Agreement” and such transactions contemplated thereby, the “ATM Program”) with A.G.P./Alliance Global Partners (the “Sales Agent”), pursuant to which the Company may offer and sell, from time to time, shares (the “Shares”) of its common stock, par value $0.001 per share (the “Common Stock”), having an aggregate offering price of up to $17.0 million through the Sales Agent, acting as agent.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1736243/000110465923118749/0001104659-23-118749-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.